End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
315 SAR | 0.00% | +0.06% | +10.92% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 64% by 2026.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 50.65 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.92% | 29.39B | C+ | ||
-14.73% | 85.42B | B- | ||
+16.05% | 84.38B | C+ | ||
-12.73% | 17.49B | B | ||
-3.17% | 16.44B | A- | ||
-1.78% | 15.28B | A- | ||
-0.45% | 12.22B | A- | ||
-31.23% | 11.98B | - | - | |
-2.51% | 11.71B | A- | ||
+26.74% | 11.64B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4013 Stock
- Ratings Dr. Sulaiman Al Habib Medical Services Group Company